YOLFTbeta
29

ABL Bio Inc

298380 · KQ · Healthcare / Biotechnology

40,650.00KRW+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close40,650.00
Open41,100.00
Day Range40,300.00 – 44,500.00
52-Week Range38,250.00 – 257,500.00
Volume278.95K
Market Cap2.19T
P/E (TTM)0.00
Forward P/E0.00
EPS-1,404.44
Dividend Yield0.00%
Beta0.28
50-Day Avg56,692.00
200-Day Avg118,504.50

About

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company offers ABL301, which is in the phase 1 clinical stage for the treatment of parkinson's disease; ABL503 and ABL111 that is in phase 1 clinical stage for the treatment of solid tumor; and ABL102 for the treatment of solid and blood tumor. It also provides ABL103 for the treatment solid cancers; ABL104 for the treatment of solid tumor; and ABL105, which is in phase 1 clinical stage for the treatment of solid tumor. ABL Bio Inc. was incorporated in 2016 and is based in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Sang Hoon Lee Ph.D.
  • Employees0
  • Headquarters456 Bongeunsa-ro, Seoul, South Korea, 06153, Korea
  • Websitehttps://www.ablbio.com

Leadership

  • Dr. Sang Hoon Lee Ph.D.Founder, President & CEO
  • Mr. Jaecheon Lee M.B.A.Executive VP, MD & CFO
  • Mr. Jung Dae Kim M.B.A.Executive VP & COO
  • Dr. Sung Ju Moon Ph.D.Executive VP & CTO
  • Dr. You Weon-Kyoo PH.D.Executive VP & Chief Scientific Officer
  • Dr. Hakju Kwon Ph.D.Senior VP, Head of Neuroscience & NCD

Financials

Income Statement

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue071.43M1.26B3.99B8.10B5.33B67.30B65.55B33.40B79.35B
Growth (%)--+1661.04%+217.12%+103.17%-34.21%+1162.19%-2.61%-49.04%+137.55%
Cost of Revenue-67.32M105.25M-------
Gross Profit-4.11M1.15B3.96B8.10B5.33B67.30B65.55B33.40B79.35B
Gross Margin-5.75%91.63%99.18%100.00%100.00%100.00%100.00%100.00%100.00%
Operating Expense-9.65B25.18B44.39B67.75B57.64B66.39B68.16B92.78B119.63B
Operating Income-3.52B-9.65B-24.03B-40.43B-59.65B-52.31B906.48M-2.62B-59.38B-40.28B
Operating Margin--13509.67%-1910.14%-1013.52%-736.00%-980.96%1.35%-3.99%-177.76%-50.76%
EBITDA------6.86B2.09B-53.08B-33.44B
EBITDA Margin------10.19%3.19%-158.92%-42.14%
Net Income-13.68B-74.73B-117.23B-37.00B-55.61B-43.56B3.21B-2.65B-55.53B-37.81B
Net Income Margin--104628.08%-9319.95%-927.68%-686.14%-816.91%4.77%-4.04%-166.24%-47.65%
R&D-6.67B18.09B39.62B52.79B41.03B48.42B52.03B74.08B93.01B
R&D as % of Total Revenue-9336.13%1438.15%993.32%651.45%769.57%71.94%79.39%221.77%117.22%
Interest Expense00095.89M72.85M41.98M1.33B2.15B36.04M993.05M
Interest Expense % of Total Revenue-0.00%0.00%2.40%0.90%0.79%1.97%3.28%0.11%1.25%

Balance Sheet

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets7.53B20.37B168.87B142.90B99.89B65.45B185.18B160.14B231.98B280.93B
Total Liabilities19.63B106.32B11.91B10.89B9.23B9.50B115.67B86.07B64.70B124.24B
Total Equity-12.10B-85.96B156.96B132.01B90.66B55.95B69.51B74.08B167.28B154.72B
Cash5.34B2.00B122.03B91.15B40.66B21.59B25.14B28.06B56.29B111.98B
Total Debt2.33B7.63B-1.08B555.34M-----
Net Debt------14.86B14.94B--

Cash Flow

Currency: KRW2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.12B-7.14B-12.67B-23.86B-47.29B-40.61B72.13B-28.36B-69.40B-41.25B
Investing Cash Flow-2.13B-16.20B-22.78B-8.26B-3.63B20.22B-71.25B29.88B-47.17B-
Financing Cash Flow10.59B20.00B155.61B-47.49M598.29M284.13M4.65B1.44B144.57B-
Capital Expenditure2.13B802.53M1.15B1.59B434.73M1.24B2.06B5.84B9.06B20.67B
Free Cash Flow-----47.93B-41.87B68.49B-34.21B-78.46B-61.92B
FCF to OCF----101.33%103.12%94.96%120.61%113.05%150.11%

Earnings

Report DateDec 31, 2018May 15, 2019Aug 14, 2019Nov 14, 2019Feb 7, 2020Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 16, 2021May 14, 2021Aug 12, 2021Nov 12, 2021Feb 11, 2022May 16, 2022Aug 12, 2022Nov 14, 2022Feb 10, 2023May 15, 2023Aug 11, 2023Nov 10, 2023Mar 29, 2024May 14, 2024Aug 9, 2024Nov 8, 2024Feb 13, 2025May 13, 2025Aug 11, 2025Nov 10, 2025Dec 31, 2025May 11, 2026Jun 30, 2026
EPS Estimate-----------------------117.76--------
EPS Actual-156.07-136.44-149.84-175.36-356.15-325.20-310.24-274.41-297.74-191.11-170.58-211.34-353.84-181.3344.81575.96-372.84509.21-216.57-85.85-261.28-249.96-237.93-1093.44-394.78-581.91819.65-394.77-510.89-260.86-262.90
Surprise-----------------------102.04%--------
Timing-Pre-marketPre-marketPre-marketPre-market-------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-market-Pre-market-

Key Statistics & Ratios

Market Cap2.19T
Enterprise Value2.08T
Trailing P/E0.00
Forward P/E0.00
Price / Sales64.02
Price / Book12.80
EPS-1,404.44
Book Value3,062.61
Revenue (TTM)34.28B
Gross Profit (TTM)34.17B
EBITDA-82.19B
Profit Margin-229.36%
Operating Margin-85.31%
Return on Equity-44.26%
Return on Assets-20.79%
Shares Outstanding55.99M
Shares Float41.57M
Beta0.28
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%